DJS Antibodies
Engineering next-generation treatments for inflammatory disease
Autoimmune and inflammatory conditions such as arthritis and inflammatory bowel disease affect millions, yet many patients don’t respond to current therapies.
DJS Antibodies has developed a proprietary antibody-discovery platform to create targeted treatments that tackle these diseases more effectively. Acquired by AbbVie in 2022 for $255m initial consideration plus additional milestones, the team is now working within AbbVie to advance a powerful new pipeline of immunology medicines, bringing next-generation therapies closer to patients.
Sector
Life Sciences
Stage
- Exited